Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I

Journal of Pharmacology and Experimental Therapeutics

Volumn 311, Issue 1, 2004, Pages 109-114

  Brunmair, Barbara ^a   Lest, Andrea ^a   Staniek, Katrin ^b   Gras, Florian ^a   Scharf, Nicole ^a   Roden, Michael ^a   Nohl, Hans ^b   Waldhäusl, Werner ^a   Fürnsinn, Clemens ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CIPROFIBRATE; CLOFIBRATE; FENOFIBRATE; GEMFIBROZIL; GLUTAMIC ACID; LACTIC ACID; MALIC ACID; PALMITIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROSIGLITAZONE; SUCCINATE DEHYDROGENASE (UBIQUINONE); SUCCINIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DYSLIPIDEMIA; ENZYME ACTIVITY; GLYCOGEN SYNTHESIS; MALE; MITOCHONDRION; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT; RESPIRATORY CHAIN; SKELETAL MUSCLE; TISSUE HOMOGENATE;

ANIMALS; ANTILIPEMIC AGENTS; ELECTRON TRANSPORT COMPLEX I; ENERGY METABOLISM; MALE; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MUSCLE, SKELETAL; OXYGEN CONSUMPTION; PROCETOFEN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 4644298829     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.068312     Document Type: Article

References (25)

1. Balfour JA, McTavish D, and Heel RC (1990) Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 40:260-290.
2. Brunmair B, Gras F, Neschen S, Roden M, Wagner L, Waldhäusl W, and Fürnsinn C (2001) Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-γ-mediated changes in gene expression. Diabetes 50:2309-2315.
3. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhäusl W, et al. (2004) Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53:1052-1059.
4. Cherkaoui Malki M, Assaka L, Pacot C, Bardot O, and Latruffe N (1991) Effect of different hypolipidemic agents on rat liver peroxisomal and mitochondrial functions and biogenesis. Cell Mol Biol 37:723-733.
5. Crettaz M, Prentki M, Zanietti D, and Jeanrenaud B (1980) Insulin resistance in soleus muscle from obese Zucker rats. Involvement of several defective sites. Biochem J 186:525-534.
6. DiMauro S and Schon EA (2003) Mitochondrial respiratory-chain diseases. N Engl J Med 348:2656-2668.
7. El-Mir M-Y, Nogueira V, Fontaine E, Avéret N, Rigoulet M, and Leverve X (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275:223-228.
8. Fürnsinn C, Ebner K, and Waldhäusl W (1995) Failure of GLP-1(7-36)amide to affect glycogenesis in rat skeletal muscle. Diabetologia 38:864-867.
9. Ginsberg HN and Stalenhoef AF (2003) The metabolic syndrome: targeting dyslipidemia to reduce coronary risk. J Cardiovasc Risk 10:121-128.
10. Guerre-Millo M, Gervois P, Raspé E, Madsen L, Poulain P, Derudas B, Herbert J-M, Winegar DA, Willson TM, Fruchart J-C, et al. (2000) Peroxisome-proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275:16638-16642.
11. Hodel C (2002) Myopathy and rhabdomyolysis with lipid lowering drugs. Toxicol Lett 128:159-168.
12. Keller BJ, Yamanaka H, and Thurman RG (1992) Inhibition of mitochondrial respiration and oxygen-dependent hepatotoxicity by six structurally dissimilar peroxisomal proliferating agents. Toxicology 71:49-61.
13. Kobayashi M, Shigeta Y, Hirata Y, Omori Y, Sakamoto N, Nambu S, and Baba S (1988) Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. Diabetes Care 11:495-499.
14. Lee CH, Olson P, and Evans RM (2003) Minireview: lipid metabolism, metabolic diseases and peroxisome proliferator-activated receptors. Endocrinology 144: 2201-2207.
15. Lee HJ, Choi SS, Park MK, An YJ, Seo SY, Kim MC, Hong SH, Hwang TH, Rang DY, Garber AJ, et al. (2002) Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem Biophys Res Commun 296: 293-299.
16. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, and Gonzalez FJ (1995) Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15:3012-3022.
17. Miller DB and Spence JD (1998) Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 34:55-162.
18. Miller RG (1981) Simultaneous Statistical Inference. Springer-Verlag, Berlin, Heidelberg, Germany.
19. Owen MR, Doran E, and Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348:607-614.
20. Qu B, Li Q-T, Wong KP, Tan TMCM, and Halliwell B (2001) Mechanism of clofibrate hepatotoxicity: mitochondrial damage and oxidative stress in hepatocytes. Free Radic Biol Med 31:659-669.
21. Rader DJ and Haffner SM (1999) Role of fibrates in the management of hypertriglyceridemia. Am J Cardiol 83:30F-35F.
22. Schoonjans K, Staels B, and Auwerx J (1996) Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37:907-925.
23. Shek A and Ferrill MJ (2001) Statin-fibrate combination therapy. Ann Pharmacother 35:908-917.
24. Tein I (1996) Metabolic myopathies. Semin Pediatr Neurol 3:59-98.
25. Zhou S and Wallace KB (1999) The effect of peroxisome proliferators on mitochondrial bioenergetics. Toxicol Sci 48:82-89.